Neurofibromatosis Research Program; Program Announcements FY16 Neurofibromatosis Research Program (NFRP) Application submission deadline for FY16 has passed. To view past program announcements, please visit the NFRP. The Fiscal Year 2011 (FY11) Defense Appropriations Act provides $16M to the Department of Defense (DOD) Neurofibromatosis Research Program (NFRP) to find and fund the best research to eradicate the clinical impact of. Program Announcement Department of Defense Congressionally Directed Medical Research Programs Neurofibromatosis Research Program Clinical Trial Award Funding Opportunity Number: W81XWH-13-NFRP-CTA Catalog. DoD FY13 NFRP Investigator-Initiated Research Award 1 Program Announcement. Department of Defense. Congressionally Directed Medical Research Programs. Neurofibromatosis Research Program. Investigator-Initiated Research.
Department of Defense Neurofibromatosis Research Program Funding Opportunities for Fiscal Year 2011 The Neurofibromatosis Research Program (NFRP) was established in 1996 to promote the understanding, diagnosis, and treatment. Army’s highly successful Neurofibromatosis Research Program (NFRP), which is now conducting clinical trials at nation-wide clinical trials centers created by NFRP funding. Microsoft Word - FY11 NF DOD testimony.doc Author.
Department of Defense NF Research Program. Consumer Reviewers for the DOD’s NF Research Program, Marissa Shaw and Lindsay Rosenfeld: Since the Department of Defense’s Congressionally Directed Medical Research Program (CDMRP) for Neurofibromatosis began in 1. NF Northeast staff as well as NF patients and family members have participated in the evaluation of research applications submitted for funding.
Consumer reviewers are full voting members, along with prominent scientists, at meetings to help determine how the money appropriated by Congress for a given fiscal year will be spent on future neurofibromatosis research. Marissa Shaw and Lindsay Rosenfeld, Consumer Representatives on the CDMRP Panel. During the current round of application reviews Marissa Shaw of New York sat on the NF2 Panel and Lindsay Rosenfeld of Massachusetts was on the NF1 Panel. Both were nominated by NF Northeast. Consumer reviewers are asked to represent the collective view of neurofibromatosis survivors and patients, family members, and persons at risk for the disease when they prepare comments on the impact of the research on issues such as disease prevention, screening, diagnosis, treatment, and quality of life after treatment. Consumer advocates and scientists work together in this unique partnership to evaluate the scientific merit of neurofibromatosis research applications.
The Consumer Reviewers on each panel are instrumental in helping the scientists understand the patient. They bring with them a sense of urgency and remind all of the human element involved in medical research. Scientists applying propose to conduct innovative neurofibromatosis research aimed at the elimination of neurofibromatosis. The NFRP fills important gaps not addressed by other funding agencies by supporting groundbreaking, high- risk, high- gain research while encouraging out- of- the- box thinking. Along with nominating consumers for the Panel, NF Northeast has been a constant advocate for the funding of this critical research by meeting annually with members of Congress to ensure the continuation of the CDMRP.